Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 02.06.2021.

#biotechnology
#pharmaceuticals
#clinicalcatchup
#immunotherapy
#Vienna
#F2G
#Covaxin
#biopharma
#pharmaceutical
#lifesciences

Companies And Industries

@Biotechnology shared
On Jun 1, 2021
Female-Founded and Funded Capsida Taps Swati Tole as Chief Medical Officer https://t.co/gVVr9N44tQ https://t.co/qeRcOSK5m7
Open
Female-Founded and Funded Capsida Taps Swati Tole as Chief Medical Officer

Female-Founded and Funded Capsida Taps Swati Tole as Chief Medical Officer

Newly entrenched in a leadership role within one of the most complex therapeutic spaces, Tole discussed the complexities of being both a woman and a woman of color in the biotech industry. 

@biospace shared
On Jun 1, 2021
Clinical Catch-Up: May 24-28 #biotechnology #pharmaceuticals #clinicalcatchup https://t.co/aVT8r7bmp0
Open
Clinical Catch-Up: May 24-28

Clinical Catch-Up: May 24-28

Heading into the U.S. Memorial Day holiday weekend and the official start of summer, it was a moderately busy week for clinical trial news. Take a look.

@Labiotech_eu shared
On May 31, 2021
#Vienna has a booming life sciences sector that has rapidly grown over the last decade. Here are 15 #biotech companies in the city you should know about, including the #immunotherapy developer @HookipaPharma and the antifungals specialist #F2G. 🇦🇹 https://t.co/EVClar8bOC
Open
The Top 15 Biotech Companies You Should Know in Vienna

The Top 15 Biotech Companies You Should Know in Vienna

Here are the top biotech companies in Vienna, a city with a booming life sciences sector that has rapidly grown over the last decade.

@biospace shared
On Jun 1, 2021
May was a busy month with seven Biotech IPOs #biotechnology #biopharma #pharmaceutical https://t.co/QToligFhuS
Open
May Was a Busy Month with Seven Biotech IPOs

May Was a Busy Month with Seven Biotech IPOs

There were seven initial public offerings (IPOs) for biotech companies in the month of May. Here’s a look.

@biospace shared
On May 28, 2021
Biopharma industry continues to address inequality, inequity in the life sciences #lifesciences #biotechnology #pharmaceuticals https://t.co/ScNTMvx8bR
Open
Biopharma Industry Continues to Address Inequality, Inequity in the Life Sciences

Biopharma Industry Continues to Address Inequality, Inequity in the Life Sciences

The biopharma industry strives to bring in more voices at the corporate level and clinical trials. But, there is still a long way to go, especially with companies helmed by minorities.

@BIRAC_2012 shared
On Jun 2, 2021
RT @DBTIndia: 📢Haffkine Biopharma to Produce 22.8 Crore Doses per year of #Covaxin under Technology Transfer Arrangement with @BharatBiotech 📄Press Release: https://t.co/FPFXomUYg2 @drharshvardhan @RenuSwarup #IndiaFightsCOVID19 #DBTFightsCOVID19 https://t.co/mzDuo0eqJ2
Open
Centre takes steps to accelerate domestic vaccine production

Centre takes steps to accelerate domestic vaccine production

Mumbai | June 2,  2021   With the aim of vaccinating the entire eligible population at the ear

@FierceBiotech shared
On May 27, 2021
The biotech was keen to stress in an 8-K SEC filing (but not a press release) that his departure was “not related to any disagreements with the Company on any matter https://t.co/v5JMecky2v
Open
Magenta Therapeutics' research lead Davis hits the exit for family reasons

Magenta Therapeutics' research lead Davis hits the exit for family reasons

Magenta Therapeutics is losing its chief medical officer and head of R&D John Davis, M.D., with his last day coming July 30.

@FierceBiotech shared
On Jun 2, 2021
Immunovant said Rita Jain, M.D., is leaving “to pursue another opportunity,” without divulging more. Jain joined the company in January. https://t.co/USohcQWzmB
Open
Immunovant's plan to restart IMVT-1401 development falls flat as CMO makes an exit

Immunovant's plan to restart IMVT-1401 development falls flat as CMO makes an exit

Call it a double whammy for Immunovant. The clinical-stage biotech hit another roadblock with its lead drug candidate, IMVT-1401, just as Chief Medical Officer Rita Jain makes an abrupt ...